MedTrace Logo

A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours

NCT01736163 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2015-03-23

No results posted yet for this study

Summary

The study is to demonstrate non-inferior thyroid remnant first ablation success of Thyrogen and 131I compared to thyroid hormone withdrawal (THW) and 131I in patients with T4 tumour based on historical diagnostic whole body scan (DxWBS) records.

Conditions

Interventions

DRUG

Thyrogen

0.9 mg IM, administrated for 2 consecutive days

DRUG

131I

28 mCi or ≥ 1.036 GBq.

OTHER

Thyroid Hormone Withdrawal

Stop taking hormone therapy

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Genzyme, a Sanofi Company

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Germany
  • Italy
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736163 on ClinicalTrials.gov